Wolfgang Seibold

2.1k total citations · 1 hit paper
15 papers, 528 citations indexed

About

Wolfgang Seibold is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Genetics. According to data from OpenAlex, Wolfgang Seibold has authored 15 papers receiving a total of 528 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Physiology and 2 papers in Genetics. Recurrent topics in Wolfgang Seibold's work include Asthma and respiratory diseases (8 papers), Inhalation and Respiratory Drug Delivery (5 papers) and Respiratory and Cough-Related Research (3 papers). Wolfgang Seibold is often cited by papers focused on Asthma and respiratory diseases (8 papers), Inhalation and Respiratory Drug Delivery (5 papers) and Respiratory and Cough-Related Research (3 papers). Wolfgang Seibold collaborates with scholars based in Germany, United States and South Africa. Wolfgang Seibold's co-authors include Ekkehard Beck, Mark Vandewalker, Huib A.M. Kerstjens, Michael Engel, Ralf Sigmund, Eric D. Bateman, Ronald Dahl, Pierluigi Paggiaro, Petra Moroni-Zentgraf and Christopher H. Goss and has published in prestigious journals such as New England Journal of Medicine, European Respiratory Journal and Thorax.

In The Last Decade

Wolfgang Seibold

12 papers receiving 514 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy

2012 476 citations Huib A.M. Kerstjens, Michael Engel et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Wolfgang Seibold

Since Specialization

Citations

This map shows the geographic impact of Wolfgang Seibold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfgang Seibold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfgang Seibold more than expected).

Fields of papers citing papers by Wolfgang Seibold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfgang Seibold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfgang Seibold. The network helps show where Wolfgang Seibold may publish in the future.

Co-authorship network of co-authors of Wolfgang Seibold

This figure shows the co-authorship network connecting the top 25 collaborators of Wolfgang Seibold. A scholar is included among the top collaborators of Wolfgang Seibold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfgang Seibold. Wolfgang Seibold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	P045 Lenticlair™ 1: A phase 1/2 trial evaluating the safety, tolerability and efficacy of an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with CF ineligible for CFTR modulators 2024 ·Journal of Cystic Fibrosis ·Jane C. Davies, Marcus Mall, Deepika Polineni, Scott H. Donaldson, Isabelle Fajac, Raksha Jain, B. K. Rubin, Alan Boyd, Deborah R. Gill, Uta Griesenbach, Stephen C. Hyde, (unknown), Mark Avis, (unknown), Ralf Sigmund, Wolfgang Seibold, A. Gupta, Eric W.F.W. Alton	0
2	The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers 2023 ·Pulmonary Pharmacology & Therapeutics ·(unknown), Jens Vogel‐Claussen, Philipp Badorrek, Meike Müller, Kathrin Hohl, (unknown), Tobias Litzenburger, Wolfgang Seibold, Abhya Gupta, Jens M. Hohlfeld	1
3	Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study 2021 ·European Respiratory Journal ·Christopher H. Goss, Isabelle Fajac, Raksha Jain, Wolfgang Seibold, Abhya Gupta, (unknown), Sivagurunathan Sutharsan, Jane C. Davies, Marcus Mall	7
4	First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers 2020 ·ERJ Open Research ·Alison E. Mackie, (unknown), (unknown), (unknown), (unknown), Wolfgang Seibold	7
5	An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF^TM1 2020 ·ERJ Open Research ·Christopher H. Goss, Raksha Jain, Wolfgang Seibold, (unknown), (unknown), Abhya Gupta, Isabelle Fajac	9
6	BI 1026706, a Bradykinin 1 Antagonist, Did Not Reduce Pulmonary Inflammation Upon Segmental Endotoxin Challenge in Healthy Current Smoker Subjects Compared with Placebo 2019 ·Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft) ·Jens M. Hohlfeld, Philipp Badorrek, Cornelia Faulenbach, Kathrin Hohl, Tobias Litzenburger, Meike Müller, (unknown), Wolfgang Seibold, Abhya Gupta	1
7	U-BIOPRED: evaluation of the value of a public–private partnership to industry 2018 ·Drug Discovery Today ·John Riley, Veit J. Erpenbeck, John G. Matthews, Cécile Holweg, Christopher Compton, Wolfgang Seibold, T. W. Higenbottam, Scott Wagers, Anthony Rowe, David Myles	11
8	Tiotropium decreases the risk of exacerbations in patients with symptomatic asthma regardless of baseline characteristics 2014 ·Pneumologie ·Ekkehard Beck, Huib A.M. Kerstjens, DP Tashkin, Michael Engel, Ronald Dahl, (unknown), Mark Vandewalker, Wolfgang Seibold, (unknown), Hendrik Schmidt, E.D. Bateman	3
9	P163 Tiotropium decreases the risk of exacerbations in patients with symptomatic asthma regardless of baseline characteristics including markers of allergic status 2013 ·Thorax ·(unknown), (unknown), DP Tashkin, Michael Engel, Ronald Dahl, Pierluigi Paggiaro, Ekkehard Beck, (unknown), Wolfgang Seibold, Petra Moroni-Zentgraf, Hendrik Schmidt, Huib A.M. Kerstjens	3
10	Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy breakdown → 2012 ·New England Journal of Medicine ·Huib A.M. Kerstjens, Michael Engel, Ronald Dahl, Pierluigi Paggiaro, Ekkehard Beck, Mark Vandewalker, Ralf Sigmund, Wolfgang Seibold, Petra Moroni-Zentgraf, Eric D. Bateman	476
11	Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines 2012 ·Huib A.M. Kerstjens, Ronald Dahl, Ekkehard Beck, Mark Vandewalker, Michael Engel, Ralf Sigmund, Wolfgang Seibold, Petra Moroni-Zentgraf, Eric D. Bateman	0
12	TIOTROPIUM PROVIDES SUSTAINED BRONCHODILATION IN PATIENTS WITH UNCONTROLLED ASTHMA AND PERSISTENT AIRFLOW OBSTRUCTION DESPITE TREATMENT IN ACCORDANCE WITH GUIDELINES 2012 ·Data Archiving and Networked Services (DANS) ·Huib A.M. Kerstjens, (unknown), Mark Vandewalker, Ekkehard Beck, Michael E. Engel, Ralf Sigmund, Wolfgang Seibold, Petra Moroni-Zentgraf, Eric D. Bateman	5
13	TIOTROPIUM REDUCES ASTHMA EXACERBATIONS IN PATIENTS WITH UNCONTROLLED ASTHMA AND PERSISTENT AIRFLOW OBSTRUCTION DESPITE TREATMENT IN ACCORDANCE WITH GUIDELINES 2012 ·Data Archiving and Networked Services (DANS) ·Huib A.M. Kerstjens, Ronald Dahl, Ekkehard Beck, Mark Vandewalker, Michael E. Engel, Ralf Sigmund, Wolfgang Seibold, (unknown), Eric D. Bateman	1
14	Tiotropium provides sustained bronchodilation in asthmatics with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines 2012 ·Huib A.M. Kerstjens, Pierluigi Paggiaro, Mark Vandewalker, Ekkehard Beck, Michael Engel, Ralf Sigmund, Wolfgang Seibold, Petra Moroni-Zentgraf, Eric D. Bateman	0
15	Effect of the antioxidant Nicanartine on the proliferative and inflammatory response after experimental balloon angioplasty 1998 ·Coronary Artery Disease ·(unknown), Sybille Hanke, Joachim Kamenz, Rainer Voisard, (unknown), Wolfgang Seibold, (unknown), G. Quack, (unknown), Hartmut Hanke	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact